Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma

A. Mikulasova, CP. Wardell, A. Murison, EM. Boyle, GH. Jackson, J. Smetana, Z. Kufova, L. Pour, V. Sandecka, M. Almasi, P. Vsianska, E. Gregora, P. Kuglik, R. Hajek, FE. Davies, GJ. Morgan, BA. Walker,

. 2017 ; 102 (9) : 1617-1625. [pub] 20170526

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, N.I.H., Extramural

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024987

Grantová podpora
NV15-29667A MZ0 CEP - Centrální evidence projektů

Monoclonal gammopathy of undetermined significance is a pre-malignant precursor of multiple myeloma with a 1% risk of progression per year. Although targeted analyses have shown the presence of specific genetic abnormalities such as IGH translocations, RB1 deletion, 1q gain, hyperdiploidy or RAS gene mutations, little is known about the molecular mechanism of malignant transformation. We performed whole exome sequencing together with comparative genomic hybridization plus single nucleotide polymorphism array analysis in 33 flow-cytometry-separated abnormal plasma cell samples from patients with monoclonal gammopathy of undetermined significance to describe somatic gene mutations and chromosome changes at the genome-wide level. Non-synonymous mutations and copy-number alterations were present in 97.0% and in 60.6% of cases, respectively. Importantly, the number of somatic mutations was significantly lower in monoclonal gammopathy of undetermined significance than in myeloma (P<10-4) and we identified six genes that were significantly mutated in myeloma (KRAS, NRAS, DIS3, HIST1H1E, EGR1 and LTB) within the monoclonal gammopathy of undetermined significance dataset. We also found a positive correlation with increasing chromosome changes and somatic gene mutations. IGH translocations, comprising t(4;14), t(11;14), t(14;16) and t(14;20), were present in 27.3% of cases and in a similar frequency to myeloma, consistent with the primary lesion hypothesis. MYC translocations and TP53 deletions or mutations were not detected in samples from patients with monoclonal gammopathy of undetermined significance, indicating that they may be drivers of progression to myeloma. Data from this study show that monoclonal gammopathy of undetermined significance is genetically similar to myeloma, however overall genetic abnormalities are present at significantly lower levels in monoclonal gammopathy of undetermined significant than in myeloma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024987
003      
CZ-PrNML
005      
20180716095621.0
007      
ta
008      
180709s2017 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2017.163766 $2 doi
035    __
$a (PubMed)28550183
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Mikulasova, Aneta $u Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Medical Genetics, University Hospital Brno, Czech Republic. Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
245    14
$a The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma / $c A. Mikulasova, CP. Wardell, A. Murison, EM. Boyle, GH. Jackson, J. Smetana, Z. Kufova, L. Pour, V. Sandecka, M. Almasi, P. Vsianska, E. Gregora, P. Kuglik, R. Hajek, FE. Davies, GJ. Morgan, BA. Walker,
520    9_
$a Monoclonal gammopathy of undetermined significance is a pre-malignant precursor of multiple myeloma with a 1% risk of progression per year. Although targeted analyses have shown the presence of specific genetic abnormalities such as IGH translocations, RB1 deletion, 1q gain, hyperdiploidy or RAS gene mutations, little is known about the molecular mechanism of malignant transformation. We performed whole exome sequencing together with comparative genomic hybridization plus single nucleotide polymorphism array analysis in 33 flow-cytometry-separated abnormal plasma cell samples from patients with monoclonal gammopathy of undetermined significance to describe somatic gene mutations and chromosome changes at the genome-wide level. Non-synonymous mutations and copy-number alterations were present in 97.0% and in 60.6% of cases, respectively. Importantly, the number of somatic mutations was significantly lower in monoclonal gammopathy of undetermined significance than in myeloma (P<10-4) and we identified six genes that were significantly mutated in myeloma (KRAS, NRAS, DIS3, HIST1H1E, EGR1 and LTB) within the monoclonal gammopathy of undetermined significance dataset. We also found a positive correlation with increasing chromosome changes and somatic gene mutations. IGH translocations, comprising t(4;14), t(11;14), t(14;16) and t(14;20), were present in 27.3% of cases and in a similar frequency to myeloma, consistent with the primary lesion hypothesis. MYC translocations and TP53 deletions or mutations were not detected in samples from patients with monoclonal gammopathy of undetermined significance, indicating that they may be drivers of progression to myeloma. Data from this study show that monoclonal gammopathy of undetermined significance is genetically similar to myeloma, however overall genetic abnormalities are present at significantly lower levels in monoclonal gammopathy of undetermined significant than in myeloma.
650    _2
$a lidské chromozomy $x genetika $7 D002877
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a monoklonální gamapatie nejasného významu $x genetika $x patologie $7 D008998
650    _2
$a mnohočetný myelom $x genetika $x patologie $7 D009101
650    _2
$a nádorové proteiny $x genetika $7 D009363
650    12
$a translokace genetická $7 D014178
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Wardell, Christopher P $u Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
700    1_
$a Murison, Alexander $u Center for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, UK.
700    1_
$a Boyle, Eileen M $u Center for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, UK.
700    1_
$a Jackson, Graham H $u Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
700    1_
$a Smetana, Jan $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Medical Genetics, University Hospital Brno, Czech Republic.
700    1_
$a Kufova, Zuzana $u Faculty of Medicine, University of Ostrava, Czech Republic. Department of Hematooncology, University Hospital Ostrava, Czech Republic.
700    1_
$a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Czech Republic.
700    1_
$a Sandecka, Viera $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Czech Republic.
700    1_
$a Almasi, Martina $u Department of Clinical Hematology, University Hospital Brno, Czech Republic.
700    1_
$a Vsianska, Pavla $u Department of Clinical Hematology, University Hospital Brno, Czech Republic.
700    1_
$a Gregora, Evzen $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Kuglik, Petr $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Medical Genetics, University Hospital Brno, Czech Republic.
700    1_
$a Hajek, Roman $u Faculty of Medicine, University of Ostrava, Czech Republic. Department of Hematooncology, University Hospital Ostrava, Czech Republic.
700    1_
$a Davies, Faith E $u Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
700    1_
$a Morgan, Gareth J $u Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
700    1_
$a Walker, Brian A $u Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA bwalker2@uams.edu.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 102, č. 9 (2017), s. 1617-1625
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28550183 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180716095919 $b ABA008
999    __
$a ok $b bmc $g 1317118 $s 1021908
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 102 $c 9 $d 1617-1625 $e 20170526 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
GRA    __
$a NV15-29667A $p MZ0
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace